Corynebacterium diphtheriae CRM197 protein
- Generic Name
- Corynebacterium diphtheriae CRM197 protein
- Brand Names
- Vaxneuvance
- Drug Type
- Biotech
- CAS Number
- 1272033-67-6
- Unique Ingredient Identifier
- 08VC9WC084
Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)
- Conditions
- Pneumococcal Infection
- Interventions
- Biological: Placebo for V110Biological: Placebo for V114
- First Posted Date
- 2021-12-15
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 850
- Registration Number
- NCT05158140
- Locations
- 🇺🇸
Valley Clinical Trials Inc. ( Site 0002), Northridge, California, United States
🇵🇷CAIMED Center - Ponce School of Medicine ( Site 0103), Ponce, Puerto Rico
🇺🇸Charlottesville Medical Research Center, LLC ( Site 0008), Charlottesville, Virginia, United States
Safety and Immunogenicity of V114 in Healthy Infants in South Korea (V114-036)
- First Posted Date
- 2020-11-18
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 58
- Registration Number
- NCT04633226
- Locations
- 🇰🇷
Jeonbuk National University Hospital ( Site 0008), Jeonju-si, Jeonrabugdo, Korea, Republic of
🇰🇷Hallym University Dongtan Sacred Heart Hospital ( Site 0013), Hwaseong-si, Kyonggi-do, Korea, Republic of
🇰🇷CHA Bundang Medical Center CHA University ( Site 0020), Seongnam si, Kyonggi-do, Korea, Republic of
V114 and Acute Otitis Media (V114-032/PNEU-ERA)
- Conditions
- Acute Otitis Media (AOM)
- Interventions
- Other: Pediatric vaccines
- First Posted Date
- 2019-12-10
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 7000
- Registration Number
- NCT04193215
- Locations
- 🇹đź‡
Panyananthaphikkhu Chonprathan Medical Center ( Site 0014), Pak Kret, Nonthaburi, Thailand
🇹đź‡Bhumibol Adulyadej Hospital ( Site 0013), Sai Mai, Krung Thep Maha Nakhon, Thailand
🇹đź‡Sappasit Prasong Hosptial-Pediatric ( Site 0016), Ubon Ratchathani, Thailand
Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025)
- Conditions
- Pneumococcal Infections
- Interventions
- First Posted Date
- 2019-07-24
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1184
- Registration Number
- NCT04031846
- Locations
- 🇧🇪
O.L.V. Ziekenhuis Aalst ( Site 0144), Aalst, Belgium
🇧🇪AZ Sint Jan Brugge-Oostende ( Site 0147), Brugge, Belgium
🇪🇸Centro de Salud Paiporta ( Site 0117), Paiporta, Valencia, Spain
Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026)
- Conditions
- Pneumococcal Infections
- Interventions
- First Posted Date
- 2019-07-11
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1191
- Registration Number
- NCT04016714
- Locations
- 🇫🇮
Kokkolan rokotetutkimusklinikka ( Site 0029), Kokkola, Mellersta Osterbotten, Finland
🇮🇹IRCCS Ospedale Policlinico San Martino ( Site 0042), Genova, Italy
🇩🇰Odense Universitetshospital ( Site 0001), Odense C, Syddanmark, Denmark
Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020)
- Conditions
- Pneumonia, PneumococcalPneumococcal Infections
- Interventions
- Drug: Prevnar 13™
- First Posted Date
- 2019-05-15
- Last Posted Date
- 2021-04-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 2340
- Registration Number
- NCT03950856
- Locations
- 🇺🇸
L&C Professional Medical Research Institute ( Site 1012), Miami, Florida, United States
🇺🇸Alpha Science Research ( Site 1015), Miami, Florida, United States
🇺🇸Advanced Clinical Research ( Site 1028), West Jordan, Utah, United States
Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-028)
- Conditions
- Pneumococcal Infections
- Interventions
- Biological: Pneumococcal 13-valent Conjugate Vaccine (PCV13)Biological: Adsorbed Diphtheria-purified Pertussis-tetanus-inactivated polio (Sabin strain) Combined Vaccine (DTaP-IPV)
- First Posted Date
- 2019-02-20
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 133
- Registration Number
- NCT03848065
- Locations
- 🇯🇵
Kubota Children's Clinic ( Site 2815), Osaka, Japan
🇯🇵Japanese Red Cross Shizuoka Hospital ( Site 2817), Shizuoka, Japan
🇯🇵Hosaka Children's Clinic ( Site 2814), Tokyo, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.